[ad_1]
A new "search and destroy" gene therapy system could potentially treat prostate cancer in the future, after stopping the majority of tumors in laboratory models at Strathclyde University and the Beatson Institute .
The system has been used against two types of prostate tumor, resulting in the disappearance of 70% of one type and 50% of the other over a period of one month. These results are a promising start for the system as it continues to progress toward the clinic.
Prostate cancer is the fourth most common cancer in the world, the second most common in men and the most prevalent in Europe and North America. It causes the death of 300,000 patients worldwide each year and its incidence has steadily increased over the last two decades.
The research was published in the journal Drug Delivery. Researchers from the Strathclyde Institute of Pharmacy and Biomedical Sciences, the Strathclyde Department of Pure and Applied Chemistry, and Glasgow Cancer Research UK Beatson Institute participated in this seminar.
Dr. Christine Dufès, Senior Lecturer at the Institute of Pharmacy and Biomedical Sciences at Strathclyde, led the research. "While some treatments, including chemotherapy and radiotherapy, may be effective against localized tumors, there is still no effective treatment for patients whose cancer recurs or spreads, which means that new therapeutic approaches are needed. urgently needed for these patients.
"Gene therapy could be very promising for the treatment of prostate cancer, but its use is currently limited by the lack of delivery systems that can selectively deliver therapeutic genes to tumors without adverse side effects to healthy tissue." .
"To solve this problem, we are developing a new nanomedicine" search and destruction "linked to an iron-bearing protein called lactoferrin, whose receptors are found in large numbers in many cancers.The results show that it is very promising. for the treatment of prostate cancer by gene therapy ".
The research was conducted on two prostate cancer cell lines, PC-3 and DU145, in the laboratory.
Intravenous administration of the nanomedicine treatment resulted in the complete disappearance of 70% of the PC-3 tumors and half of the DU145 prostate tumors within a month.
The research was funded by Worldwide Cancer Research – formerly AICR.
Dr. Matthew Lam, Head of Scientific Communications at Worldwide Cancer Research, said, "We are delighted to see that this research is making progress that may one day see the gene therapy used to treat cancer patients The smart chemistry used in this study to deliver the treatment to the heart of the tumor is a promising advance.
"We thank the brilliant supporters of Worldwide Cancer Research, whose generous donations have made this research possible."
Source:
https://www.strath.ac.uk/
[ad_2]
Source link
